Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs LCL 161 (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
- Focus Adverse reactions
- 13 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 27 Jul 2017.
- 26 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
- 16 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.